FDA clears Glenmark’s generic Firazyr
Firazyr injection had a market value of roughly $223.4 million for the 12 months ended March 2021, according to IQVIA.
The Food and Drug Administration has given the green light to Glenmark for icatibant injection, 30 mg/3 ml (10 mg/ml) single-dose prefilled syringe.
The medication is the generic of Shire Human Genetic Therapies’ Firazyr. It is used to treat acute attacks of hereditary angioedema in adults 18 years of age and older.
This marks Glenmark's first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, N.C.
Firazyr injection, 30 mg/3 ml (10 mg/ml) single-dose prefilled syringe had a market value of approximately $223.4 million for the 12 months ended March 2021, according to IQVIA.